One of the callers in the cc raised a very valid a

One of the callers in the cc raised a very valid and differentiating point between Remdesivir and Leronlimab. I believe it was Dr. John Abeles a well know bio investor. He pointed out that Remdesivir being an IV based process was much more cumbersome and would be limited in it’s use for the broader usage by medical practitioners who operate in clinics and doctors offices. Leronlimab being a subcutaneous injection would be done at the onset of the diagnosis safely at the doctor’s office as in the recent mm trial (not hospital) and arrest the potential of the disease progressing. Hence serving the unmet need of this disease population.